Last Update 01 Feb 26

Fair value Increased 5.58%

MRNA: Cancer Vaccine Risk And Vaccine Backlash Will Restrain Long-Term Upside

The analyst price target for Moderna has increased by about $2 to $38.80, as analysts incorporate updated assumptions for slightly stronger revenue growth, modestly better profit margins, a marginally lower discount rate, and a slightly reduced future P/E multiple.

Analyst Commentary

Recent Street research on Moderna shows a mix of cautious optimism and ongoing concern. Price targets have been adjusted in both directions, and ratings range from Underperform to Neutral and Equal Weight, which gives you a fairly balanced view of how execution risk and valuation are being weighed.

Bullish Takeaways

Some bullish analysts are raising price targets after updating models for revenue and margin assumptions, indicating they see Moderna's current valuation as more aligned with their refreshed outlook.
Several research updates highlight efforts to improve gross margins and manage operating expenses, which contributes to a more constructive view on the path toward better profitability metrics over time.
The 5 year term loan facility of up to US$1.5b, with a US$600m initial draw, is viewed by some as a supportive capital move that preserves equity, improves liquidity and may reduce perceived balance sheet risk.
The European Patent Office ruling, described as a clear win for Moderna, is seen as a positive for intellectual property strength and is incorporated into long term earnings power assumptions in some models.

Bearish Takeaways

Bearish analysts keeping Underperform or similar ratings often point to limited visibility on meaningful revenue growth and on the timing of reaching break even or profitability, which weighs on their valuation work.
Several reports flag that Moderna's shares may continue to trade around COVID vaccine uptake and sentiment, with expectations that related headwinds could persist into the 2026 and 2027 seasons, adding uncertainty to near term cash flow forecasts.
Some analysts emphasize that risk and reward for the Phase 3 cancer vaccine data in adjuvant melanoma appears balanced but very binary, which keeps them cautious on assigning high upside in their models before more data is available.
Ongoing IP litigation and the possibility of a substantial royalty award or settlement are cited as overhangs that could affect valuation, even as added debt funding improves Moderna's position as a counter party.

What's in the News

Moderna's chief is reported to be curbing investment in vaccine trials in response to U.S. political backlash around vaccines. This could affect the pace and scope of future clinical programs (Bloomberg).
The European Patent Office is reported to have ruled against Arbutus Biopharma in a patent appeal. Periodical coverage frames this as a win for Moderna in ongoing intellectual property disputes related to mRNA technology (Bloomberg).
Federal health officials have revised the recommended childhood vaccine schedule in the U.S., cutting the number of routinely recommended diseases to 11 from 17. This may influence long-term demand patterns across the vaccine sector that includes Moderna (New York Times).
U.S. Health Secretary Robert F. Kennedy Jr. is reported to have directed the CDC to adjust website language so it no longer labels the claim that vaccines do not cause autism as "evidence based." This is drawing renewed public attention to vaccine safety debates that include companies like Moderna (New York Times).
A CDC webpage now states that studies have not ruled out the possibility that infant vaccines may cause autism. This has intensified public discussion around vaccine risk and could shape sentiment toward vaccine makers such as Moderna (Wall Street Journal).

Valuation Changes

Fair Value: The analyst fair value estimate has risen slightly from US$36.75 to US$38.80.
Discount Rate: The discount rate has edged lower from 7.11% to about 7.09%.
Revenue Growth: Assumed long-term revenue growth has been marked up from roughly 10.37% to about 11.47%.
Net Profit Margin: Modeled profit margin has increased modestly from about 16.24% to roughly 16.96%.
Future P/E: The future P/E multiple assumption has been trimmed from about 37.53x to roughly 36.81x.

63 views

Key Takeaways

Expansion of the mRNA pipeline and strong regulatory engagement are set to diversify revenue and accelerate commercialization across infectious diseases and oncology.
Cost-cutting measures, AI adoption, and stable government contracts are driving margin improvement, operational efficiency, and more predictable revenue streams.
Slowing vaccine sales, higher competition, cost cuts, regulatory pressures, and limited capital flexibility threaten Moderna's revenue stability, pipeline breadth, and long-term earnings growth.

Catalysts

About Moderna

A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.What are the underlying business or industry changes driving this perspective?

The dramatic expansion and advancement of Moderna's mRNA pipeline beyond COVID-19-including recent positive late-stage data and upcoming filings for flu, RSV, CMV, oncology, and rare diseases-are likely to diversify the revenue base, capitalize on the rising global burden of infectious and chronic diseases, and materially boost future top-line growth.
Regulatory momentum and robust relationships with agencies (as reflected in multiple recent FDA approvals and ongoing engagement for pipeline submissions) position the company to benefit from accelerated approval pathways, enabling faster commercialization of innovative products and unlocking earlier revenue streams.
Cost structure transformation-including significant workforce reductions, manufacturing and procurement efficiencies, and ongoing R&D prioritization-puts Moderna on course to more than halve operating expenses by 2027 and target cash breakeven by 2028, driving considerable improvements in net margins and future earnings leverage.
Increasing adoption of AI and advanced analytics throughout the organization is expected to accelerate R&D productivity, speed up drug discovery, and enable more efficient commercialization, supporting both margin expansion and pipeline success in a sector being transformed by digital innovation.
Stable government and advanced purchase agreements for vaccines, combined with sustained investment in pandemic preparedness and biosecurity, create durable and predictable revenue channels amid uncertainty in vaccination rates, while also supporting Moderna's positioning as a rapid-response partner for public and private health needs.

Moderna Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Moderna's revenue will grow by 4.6% annually over the next 3 years.
Analysts are not forecasting that Moderna will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Moderna's profit margin will increase from -94.3% to the average US Biotechs industry of 14.2% in 3 years.
If Moderna's profit margin were to converge on the industry average, you could expect earnings to reach $498.6 million (and earnings per share of $1.24) by about September 2028, up from $-2.9 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.7 billion in earnings, and the most bearish expecting $-2.8 billion.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 43.5x on those 2028 earnings, up from -3.3x today. This future PE is greater than the current PE for the US Biotechs industry at 15.3x.
Analysts expect the number of shares outstanding to grow by 1.11% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.8%, as per the Simply Wall St company report.

Moderna Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Sustained decline in COVID-19 vaccine revenues and continued seasonality in the respiratory vaccine portfolio expose Moderna to ongoing revenue volatility, with pipeline diversification and non-seasonal products not yet adequately compensating for this downturn; this may result in pressure on both revenue growth and earnings consistency if replacement products underperform.
Intensifying competitive pressures in both the COVID-19 and RSV vaccine markets, coupled with uncertainty in vaccination rates and pricing (especially in the U.S.), threaten Moderna's ability to maintain market share and realize premium pricing, which could compress revenues and net margins over time.
Heavy reliance on cost reduction strategies-including significant R&D cuts, portfolio prioritization, and a 10% workforce reduction-risks constraining future innovation and pipeline productivity if new launches or late-stage program results disappoint, potentially resulting in persistent net losses and margin weakness.
Increasing regulatory scrutiny and shifting government policies, particularly on drug pricing, reimbursement, and approval requirements (noted across the company's remarks regarding evolving regulatory interactions), could delay new product launches, limit pricing power, and further compress profit margins, negatively impacting future earnings.
The company's strategy to seek external partners or financing (rather than self-funding) for key pipeline assets in high-potential but expensive clinical areas (like latent vaccines and rare diseases) reflects limited internal capital flexibility; this may restrict long-term pipeline breadth, reduce the probability of blockbuster diversification, and ultimately limit long-term revenue growth and earnings potential.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $44.25 for Moderna based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $198.0, and the most bearish reporting a price target of just $15.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $3.5 billion, earnings will come to $498.6 million, and it would be trading on a PE ratio of 43.5x, assuming you use a discount rate of 6.8%.
Given the current share price of $24.47, the analyst price target of $44.25 is 44.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Moderna?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Oncology Advancements And Evolving Policy Will Shape Recovery Amid Regulatory Shifts